By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Aprea Therapeutics, Inc. insiders have been one-way buyers this past year: three people put roughly $61,000 into the stock and nobody sold with their own money.
Duey Marc (Director) made the biggest buy, worth around $25,000. Notably, at least one C-suite executive was among the buyers.
On the institutional side, 28 funds reported holding APRE at the end of Q2 2026, and more funds bought than sold. Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 3 of the last 7 full quarters.
Are insiders buying or selling APRE stock?
In the last 12 months Aprea Therapeutics, Inc. insiders made open-market purchases worth about $61,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in APRE?
The most recent open-market insider trade in APRE was filed on 2026-02-02.
How many institutions own APRE?
28 investment managers reported holding APRE in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded APRE?
No congressional trades in APRE were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).